1. Participants with BRAF V600 mutation-positive small-cell lung cancer, Erdheim Chester Disease (ECD) and Langerhan’s-Cell Histiocytosis (LCH) demonstrated a modest but statistically significant response rate to treatment with vemurafenib. 2. Participants with BRAF V600 mutation-positive colorectal cancer did not demonstrate appreciable response rates to vemurafenib monotherapy or vemurafenib with cetuximab on a whole. Evidence Rating:
↧
